283 related articles for article (PubMed ID: 33174655)
1. Generation of universal and hypoimmunogenic human pluripotent stem cells.
Ye Q; Sung TC; Yang JM; Ling QD; He Y; Higuchi A
Cell Prolif; 2020 Dec; 53(12):e12946. PubMed ID: 33174655
[TBL] [Abstract][Full Text] [Related]
2. Universal and hypoimmunogenic pluripotent stem cells for clinical usage.
Sung TC; Maitiruze K; Pan J; Gong J; Bai Y; Pan X; Higuchi A
Prog Mol Biol Transl Sci; 2023; 199():271-296. PubMed ID: 37678974
[TBL] [Abstract][Full Text] [Related]
3. Transient characteristics of universal cells on human-induced pluripotent stem cells and their differentiated cells derived from foetal stem cells with mixed donor sources.
Sung TC; Jiang YP; Hsu JY; Ling QD; Chen H; Kumar SS; Chang Y; Hsu ST; Ye Q; Higuchi A
Cell Prolif; 2021 Mar; 54(3):e12995. PubMed ID: 33522648
[TBL] [Abstract][Full Text] [Related]
4. Generation of hypoimmunogenic human pluripotent stem cells via expression of membrane-bound and secreted β2m-HLA-G fusion proteins.
Shi L; Li W; Liu Y; Chen Z; Hui Y; Hao P; Xu X; Zhang S; Feng H; Zhang B; Zhou S; Li N; Xiao L; Liu L; Ma L; Zhang X
Stem Cells; 2020 Nov; 38(11):1423-1437. PubMed ID: 32930470
[TBL] [Abstract][Full Text] [Related]
5. Hypoimmunogenic human pluripotent stem cells are valid cell sources for cell therapeutics with normal self-renewal and multilineage differentiation capacity.
Chen Y; Zhou Y; Zhou Z; Fang Y; Ma L; Zhang X; Xiong J; Liu L
Stem Cell Res Ther; 2023 Jan; 14(1):11. PubMed ID: 36691086
[TBL] [Abstract][Full Text] [Related]
6. Human Leukocyte Antigen Class I and II Knockout Human Induced Pluripotent Stem Cell-Derived Cells: Universal Donor for Cell Therapy.
Mattapally S; Pawlik KM; Fast VG; Zumaquero E; Lund FE; Randall TD; Townes TM; Zhang J
J Am Heart Assoc; 2018 Dec; 7(23):e010239. PubMed ID: 30488760
[TBL] [Abstract][Full Text] [Related]
7. CRISPR/Cas9 genome editing in human pluripotent stem cells: Harnessing human genetics in a dish.
González F
Dev Dyn; 2016 Jul; 245(7):788-806. PubMed ID: 27145095
[TBL] [Abstract][Full Text] [Related]
8. A Scaled Framework for CRISPR Editing of Human Pluripotent Stem Cells to Study Psychiatric Disease.
Hazelbaker DZ; Beccard A; Bara AM; Dabkowski N; Messana A; Mazzucato P; Lam D; Manning D; Eggan K; Barrett LE
Stem Cell Reports; 2017 Oct; 9(4):1315-1327. PubMed ID: 29020615
[TBL] [Abstract][Full Text] [Related]
9. Generation of hypoimmunogenic human pluripotent stem cells.
Han X; Wang M; Duan S; Franco PJ; Kenty JH; Hedrick P; Xia Y; Allen A; Ferreira LMR; Strominger JL; Melton DA; Meissner TB; Cowan CA
Proc Natl Acad Sci U S A; 2019 May; 116(21):10441-10446. PubMed ID: 31040209
[TBL] [Abstract][Full Text] [Related]
10. Hypoimmunogenic Human Pluripotent Stem Cells as a Powerful Tool for Liver Regenerative Medicine.
Trionfini P; Romano E; Varinelli M; Longaretti L; Rizzo P; Giampietro R; Caroli A; Aiello S; Todeschini M; Casiraghi F; Remuzzi G; Benigni A; Tomasoni S
Int J Mol Sci; 2023 Jul; 24(14):. PubMed ID: 37511568
[TBL] [Abstract][Full Text] [Related]
11. Protocol for the Generation of Human Pluripotent Reporter Cell Lines Using CRISPR/Cas9.
Zhong A; Li M; Zhou T
STAR Protoc; 2020 Sep; 1(2):. PubMed ID: 33073252
[TBL] [Abstract][Full Text] [Related]
12. Developing CRISPR/Cas9-Mediated Fluorescent Reporter Human Pluripotent Stem-Cell Lines for High-Content Screening.
Vojnits K; Nakanishi M; Porras D; Kim Y; Feng Z; Golubeva D; Bhatia M
Molecules; 2022 Apr; 27(8):. PubMed ID: 35458632
[TBL] [Abstract][Full Text] [Related]
13. Generation of individualized immunocompatible endothelial cells from HLA-I-matched human pluripotent stem cells.
Song C; Wang L; Li Q; Liao B; Qiao W; Li Q; Dong N; Li L
Stem Cell Res Ther; 2022 Feb; 13(1):48. PubMed ID: 35109922
[TBL] [Abstract][Full Text] [Related]
14. Generating CRISPR-Cas9-Mediated Null Mutations and Screening Targeting Efficiency in Human Pluripotent Stem Cells.
Bower OJ; McCarthy A; Lea RA; Alanis-Lobato G; Zohren J; Gerri C; Turner JMA; Niakan KK
Curr Protoc; 2021 Aug; 1(8):e232. PubMed ID: 34432381
[TBL] [Abstract][Full Text] [Related]
15. Semi-automated optimized method to isolate CRISPR/Cas9 edited human pluripotent stem cell clones.
Frank E; Cailleret M; Nelep C; Fragner P; Polentes J; Herardot E; El Kassar L; Giraud-Triboult K; Monville C; Ben M'Barek K
Stem Cell Res Ther; 2023 Apr; 14(1):110. PubMed ID: 37106426
[TBL] [Abstract][Full Text] [Related]
16. Targeted Disruption of the β2-Microglobulin Gene Minimizes the Immunogenicity of Human Embryonic Stem Cells.
Wang D; Quan Y; Yan Q; Morales JE; Wetsel RA
Stem Cells Transl Med; 2015 Oct; 4(10):1234-45. PubMed ID: 26285657
[TBL] [Abstract][Full Text] [Related]
17. Selective deletion of human leukocyte antigens protects stem cell-derived islets from immune rejection.
Parent AV; Faleo G; Chavez J; Saxton M; Berrios DI; Kerper NR; Tang Q; Hebrok M
Cell Rep; 2021 Aug; 36(7):109538. PubMed ID: 34407395
[TBL] [Abstract][Full Text] [Related]
18. Generation and validation of CRISPR-engineered human natural killer cell lines for research and therapeutic applications.
Kumar A; Lee SJ; Liu Q; Chan AKN; Pokharel SP; Yu J; Chen CW; Swaminathan S
STAR Protoc; 2021 Dec; 2(4):100874. PubMed ID: 34746857
[TBL] [Abstract][Full Text] [Related]
19. Efficient scarless genome editing in human pluripotent stem cells.
Ikeda K; Uchida N; Nishimura T; White J; Martin RM; Nakauchi H; Sebastiano V; Weinberg KI; Porteus MH
Nat Methods; 2018 Dec; 15(12):1045-1047. PubMed ID: 30504872
[TBL] [Abstract][Full Text] [Related]
20. A Cell-Based Optimised Approach for Rapid and Efficient Gene Editing of Human Pluripotent Stem Cells.
Cuevas-Ocaña S; Yang JY; Aushev M; Schlossmacher G; Bear CE; Hannan NRF; Perkins ND; Rossant J; Wong AP; Gray MA
Int J Mol Sci; 2023 Jun; 24(12):. PubMed ID: 37373413
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
